The growth of the market for diabetic devices is directly proportional to the increasing diabetic population in the country. The diabetic population in the United Kingdom has been increasing constantly over the past decade. There are almost 4.5 million people living with diabetes and close to 1 million undiagnosed diabetic patients in the country. Type 2 diabetes accounts for close to 92% of the diabetic population in the country. The increasing number of type 2 diabetic population has a direct correlation to the growing obesity population. The Type 1 diabetic population is expected to see an average increase of 2.5% per year from 2012-2023. The increasing diabetic population acts as a prominent driver for the diabetic devices market in the United Kingdom.
The UK diabetes device market is broadly segmented based on type, into glucose
monitoring devices market and the management devices market. The glucose monitoring devices
market is further segmented into blood glucose meter, blood glucose testing strip, lancet and
continuous glucose monitoring device (CGM). Based on insulin delivery devices, the management devices market is further segmented as syringes, pens, pumps and injectors.
In the insulin delivery devices market in the United Kingdom, the insulin cartridge market and insulin pens market account for high market share. The growing demand for insulin has led to tremendous research and development activities on manufacturing different painless types of insulin deliverable devices, such as insulin pens. Initially syringes were the only form of insulin delivery system, and were considered to be painful and not user friendly. Thus, the companies like Novo Nordisk, Sanofi among others have produced their own insulin pens. They have a specific set dosage, and are not only less painful to use, but also reduces wastage of insulin. The high cost of insulin pens is the only prominent restraining factor for the growth of the market.
The United Kingdom has a high number of diabetic population, which accelerates the growth of the devices market. The insulin delivery devices accounted for 68% of the total UK devices market. The United Kingdom insulin delivery devices market was valued at 162.03 million in 2017 and expected to witness a CAGR of 3.34% during the forecast period (2018-2023).
Source: Mordor Intelligence Analysis
Key Players:
Dexcom, Abbott, Johnson and Johnson, Ok biotech, Medtronic, Novo Nordisk, Insujet, Sanofi, and Eli Lilly
Key Developments:
Feb 2018: Dexcom acquired TypeZero Technologies, Paving the way for automated insulin delivery. The acquisition has sent Dexcom ahead on its way in the race to create an artificial pancreas system, rather than simply offering a continuous glucose monitoring device.
Report Scope:
|
Attribute |
Details |
|
Base year for estimation |
2017 |
|
Review Period |
2012-2017 |
|
Forecast Period |
2018 – 2023 |
|
Market Representation |
Revenue in USD million and CAGR from 2018 – 2023 |
|
Regions covered |
United Kingdom |
|
Report coverage |
Revenue forecast and market dynamics |
Reasons to Purchase this Report:
- The current and future market outlook on the UK diabetes devices market
- Various perspectives of the market with the help of Porter’s five forces analysis
- Detailed analysis of the segment that is expected to dominate the market
- Regions that are expected to witness fastest growth during the forecast period
- The latest developments and strategies employed by the major market players
- 3-month analyst support, along with the Market Estimate sheet in Excel
Report Customization and Benefits:
This report can be customized to meet the desired requirements. Please connect with our analyst, who will ensure that you will get a report that suits your needs.
1. Introduction
1.1 Scope of Study
1.2 Market Definition
1.3 Executive Summary
2. Research Methodology
2.1 Study Deliverables
2.2 Study Assumptions
2.3 Research Phases
3. Market Insights
3.1 Technology Trends
3.2 Industry Attractiveness - Porter's Five Forces Analysis
3.2.1 Bargaining Power of the Suppliers
3.2.2 Bargaining Power of the Consumers
3.2.3 Threat of New Entrants
3.2.4 Threat of Substitute Products and Services
3.2.5 Competitive Rivalry within the Industry
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
5. Market Indicators
5.1 Total Diabetes Population
5.2 Type 1 Diabetes Population
5.3 Type 2 Diabetes Population
6. Market Segmentation and Analysis
6.1 Monitoring Device
6.1.1 Self Blood Glucose Monitoring
6.1.1.1 Glucometer Device
6.1.1.1.1 Blood Glucose Meters
6.1.1.1.1.1 Blood Glucose Meters, Revenue (2012-2023)
6.1.1.1.1.2 Blood Glucose Meters, Volume (2012-2023)
6.1.1.2 Glucometer consumables
6.1.1.2.1 Blood Glucose Test strips
6.1.1.2.1.1 Blood Glucose Test strips, Revenue (2012-2023)
6.1.1.2.1.2 Blood Glucose Test strips, Volume (2012-2023)
6.1.1.2.2 Lancets
6.1.1.2.2.1 Lancets, Revenue (2012-2023)
6.1.1.2.2.2 Lancets, Volume (2012-2023)
6.1.2 Continous Blood Glucose Monitoring
6.1.2.1 Durables
6.1.2.1.1 Durables, Revenue (2012-2023)
6.1.2.1.2 Durables, Volume (2012-2023)
6.1.2.2 Sensors
6.1.2.2.1 Sensors, Revenue (2012-2023)
6.1.2.2.2 Sensors, Volume (2012-2023)
6.2 Management Device
6.2.1 Insulin Pump
6.2.1.1 Insulin Pump Device
6.2.1.1.1 Insulin Pump Devices, Revenue (2012-2023)
6.2.1.1.2 Insulin Pump Devices, Volume (2012-2023)
6.2.1.2 Insulin Pump Reservoir
6.2.1.2.1 Insulin Pump Reservoirs, Revenue (2012-2023)
6.2.1.2.2 Insulin Pump Reservoirs, Volume (2012-2023)
6.2.1.3 Infusion Set
6.2.1.3.1 Infusion Sets, Revenue (2012-2023)
6.2.1.3.2 Infusion Sets, Volume (2012-2023)
6.2.2 Syringes
6.2.2.1 Syringes, Revenue (2012-2023)
6.2.2.2 Syringes, Volume (2012-2023)
6.2.3 Cartridges
6.2.3.1 Cartridges, Revenue (2012-2023)
6.2.3.2 Cartridges, Volume (2012-2023)
6.2.4 Disposable Pens
6.2.4.1 Disposable Pens, Revenue(2012-2023)
6.2.4.2 Disposable Pens, Volume (2012-2023)
6.2.5 Jet Injectors
6.2.5.1 Jet Injectors , Revenue (2012-2023)
6.2.5.2 Jet Injectors , Volume (2012-2023)
7. Key Player Profiles
7.1 Abbott Diabetes Care
7.2 Roche
7.3 Johnson & Johnson
7.4 Arkray
7.5 Ascensia Diabetes Care
7.6 AgaMatrix, Inc.
7.7 LifeScan
7.8 Sanofi
7.9 Dexcom
7.10 Medtronic
7.11 Novo Nordisk
7.12 Becton Dickinson
7.13 Eli Lilly
7.14 Novonordisk
7.15 Ypsomed Holding AG
* Each Company Profile include overview, Revenue, Product and services, Swot, Recent Activities and strategic Analysis.
